FDA Approves Zepbound® (Tirzepatide) as the First Prescription Treatment for Sleep Apnea in Adults with Obesity

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Zepbound® (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This groundbreaking approval offers hope to millions of individuals who suffer from these interconnected conditions.























